A detailed history of Trexquant Investment LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 30,976 shares of STOK stock, worth $418,485. This represents 0.01% of its overall portfolio holdings.

Number of Shares
30,976
Previous 39,800 22.17%
Holding current value
$418,485
Previous $209,000 100.0%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$4.12 - $14.17 $36,354 - $125,036
-8,824 Reduced 22.17%
30,976 $418,000
Q4 2023

Feb 09, 2024

SELL
$3.37 - $5.4 $295,821 - $474,017
-87,781 Reduced 68.8%
39,800 $209,000
Q3 2023

Nov 13, 2023

BUY
$3.78 - $11.99 $301,587 - $956,622
79,785 Added 166.93%
127,581 $502,000
Q2 2023

Aug 11, 2023

SELL
$7.93 - $13.82 $617,183 - $1.08 Million
-77,829 Reduced 61.95%
47,796 $508,000
Q1 2023

May 15, 2023

BUY
$7.65 - $10.38 $291,434 - $395,436
38,096 Added 43.52%
125,625 $1.05 Million
Q4 2022

Feb 13, 2023

BUY
$7.07 - $15.69 $266,348 - $591,089
37,673 Added 75.56%
87,529 $807,000
Q3 2022

Nov 14, 2022

SELL
$12.56 - $22.53 $424,540 - $761,536
-33,801 Reduced 40.4%
49,856 $640,000
Q2 2022

Aug 11, 2022

BUY
$10.36 - $23.93 $699,413 - $1.62 Million
67,511 Added 418.13%
83,657 $1.11 Million
Q1 2022

May 13, 2022

SELL
$17.19 - $26.1 $176,249 - $267,603
-10,253 Reduced 38.84%
16,146 $340,000
Q4 2021

Feb 14, 2022

BUY
$18.11 - $30.72 $478,085 - $810,977
26,399 New
26,399 $633,000
Q3 2021

Nov 12, 2021

SELL
$23.65 - $34.44 $211,643 - $308,203
-8,949 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$30.53 - $41.09 $32,148 - $43,267
1,053 Added 13.34%
8,949 $301,000
Q1 2021

May 13, 2021

BUY
$36.08 - $69.81 $284,887 - $551,219
7,896 New
7,896 $307,000

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $533M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.